Dx Profiler: Can Metastatic Cancer with Diagnostic Ambiguity Be Treated Based on Mutational Status Alone?

  • Review of the Initial Results from Basket Trials
  • Implications of Initial Results in Patients with Metastatic Cancer and Diagnostic Ambiguity
  • Improving Diagnostic Certainty: The Role of Molecular Assays in Challenging Cases
  • Performance of the CancerTYPE ID Molecular Classifier
Can Metastatic Cancer with Diagnostic Ambiguity Be Treated Based on Mutational Status Alone?

The application of molecularly targeted cancer therapies has rapidly expanded in the past 2 decades. The identification of genetic mutations in tumors has led to a growing list of therapies developed to specifically target those alterations. Indeed, molecularly targeted therapies—along with predictive biomarker testing and site-specific chemotherapy—have significantly improved the [ Read More ]

Wayne Kuznar